On Tuesday, Shares of BlackBerry Ltd (NASDAQ:BBRY), lost -4.44% to $6.02.
BlackBerry declared that it has accomplished the acquisition of AtHoc, a leading provider of secure, networked crisis communications. AtHoc will operate as a division of BlackBerry. AtHoc’s Chief Executive Officer, Guy Miasnik, will lead the division as part of BlackBerry’s senior leadership team reporting to John Chen, Executive Chairman and Chief Executive Officer.
The AtHoc software platform enables people, devices and organizations to exchange critical information in real time during business continuity and life safety operations. The platform securely connects with a diverse set of endpoints, counting mobile devices running iOS and Android, PC and Mac desktops, digital displays, radios, IP phones, sirens, fire panels and speakers to facilitate partnership and enhance situational awareness. AtHoc is recognized as a “Leader” by industry analyst firm Gartner, and at the highest position for ability to execute on the firm’s Magic Quadrant for U.S. Emergency/Mass Notification Services.
AtHoc has customers around the world in both the public and private sectors, and is the leading crisis communications provider to the U.S. Departments of Defense (DoD) and Homeland Security (DHS). AtHoc assists safeguard millions of people and thousands of organizations, counting leading international corporations in high technology, heavy industry, and other mission critical industries counting healthcare institutions and the vast majority of U.S. federal agencies - counting the U.S. Department of the Treasury, U.S. Department of Energy, the Centers for Disease Control and the Food and Drug Administration.
BlackBerry Limited (BlackBerry) is a provider of mobile communications and services. The Company is engaged primarily in the provision of the BlackBerry wireless solution, consisting of smartphones, service and software.
Shares of Wells Fargo & Co (NYSE:WFC), inclined 0.99% to $50.87, during its last trading session.
Wells Fargo Commercial Banking, No. 1 in new lead banking relationships with middle-market companies, expanded its administration team in Oregon by promoting two seasoned finance executives. Karen Vineyard will lead the Portland Regional Commercial Banking Office (RCBO), and Sally Williams will lead the Greater Oregon RCBO, located in Eugene, Ore. Williams succeeds Michael McEntee, a longtime Wells Fargo Commercial Banking leader in Eugene, who stepped down Sept. 1.
Vineyard and Williams, both senior vice presidents, oversee middle-market commercial bank clients with annual revenues greater than $20 million. These companies represent a broad spectrum of industries, counting manufacturing, wholesale, retail, distribution, construction, cleantech and services. Wells Fargo has more than 70 local bankers dedicated to middle-market companies in the region. The Oregon territory comprises five RCBOs, plus southwest Washington and eastern Idaho. Vineyard and Williams will focus on the planned development of business relationships across the region.
Over the past few years, Wells Fargo Commercial Banking has grown rapidly across Oregon, with specialized operations in forest products, technology, and agriculture, among others.
Wells Fargo & Company is a financial and bank holding company. Its principal business is to act as a holding company for its subsidiaries. The Company is a diversified financial services company.
Shares of Merck & Co., Inc. (NYSE:MRK), inclined 0.45% to $48.64, during its last trading session.
Syndax Pharmaceuticals, Inc. and Merck (MRK), known as MSD outside the United States and Canada, recently declared the dosing of the first patients in the Phase 1b/2 clinical trial of Syndax’s entinostat in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with non-small cell lung cancer (NSCLC) or melanoma. The clinical trial, designated ENCORE 601 by Syndax and KEYNOTE 142 by Merck, is evaluating the safety, tolerability and efficacy of entinostat, an oral, small molecule that targets immune regulatory cells, combined with KEYTRUDA, an anti-programmed cell death protein 1 (anti-PD-1) antibody.
The ENCORE 601/KEYNOTE 142 trial is designed as a Phase 1b/2 open label clinical trial with dose escalation for entinostat, in which the Phase 1b portion will evaluate the safety and tolerability of the combination of entinostat and KEYTRUDA in patients with NSCLC, and the Phase 2 portion will assess the safety and preliminary efficacy of the combination in separate cohorts in patients with NSCLC or melanoma. The trial will be conducted in the United States and is predictable to enroll up to 178 patients.
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures.
Finally, CVS Health Corp (NYSE:CVS), ended its last trade with -1.38% loss, and closed at $95.12.
CVS/pharmacy, the retail division of CVS Health (CVS), is reinforcing its longstanding commitment in the fight against the nationwide epidemic of prescription drug abuse with a number of efforts launching this month.
CVS/pharmacy has expanded the availability of the opioid overdose reversal medicine, naloxone, in several states. The medication was already available at CVS/pharmacy without a prescription in Rhode Island and Massachusetts. Naloxone is now available without a prescription at CVS/pharmacy locations in 12 additional states: Arkansas, California, Minnesota, Mississippi, Montana, New Jersey, North Dakota, Pennsylvania, South Carolina, Tennessee, Utah and Wisconsin.
In addition, CVS Health is presently participating in a research project with Boston Medical Center and Rhode Island Hospital to support a demonstration project of pharmacy-based naloxone rescue kits to assist reduce opioid addiction and overdose deaths.
CVS/pharmacy has also renewed its Medication Disposal for Safer Communities Program, in which it has teamed up with the Partnership for Drug-Free Kids to donate drug collection units to police departments around the country to assist their communities safely dispose of unwanted medications, counting controlled substances.
CVS Health Corporation, together with its subsidiaries, is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail Pharmacy and Corporate. The Pharmacy Services segment provides a range of pharmacy benefit management (PBM) services and operates under the CVS/caremark Pharmacy Services, Novologix and Navarro Health Services names.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
